Early Post-Stroke Seizures in Acute Ischemic Stroke: A Prospective Cohort Study

Ayush Agarwal, Jyoti Sharma, M.V. Padma Srivastava, Rohit Bhatia, Mamta Bhushan Singh, Anu Gupta, Awadh K. Pandit, Rajesh Singh, Roopa Rajan, Sadanand Dwivedi, Ashish Upadhyay, Ajay Garg, Venugopalan Y. Vishnu

Department of Neurology, 1Biostatistics and 2Neuroradiology, All India Institute of Medical Sciences, New Delhi, India

Abstract

Introduction: Stroke is the most common cause of epilepsy in the adult population. Post-stroke seizures (PSSs) are classified into early-onset seizures (ES) and late-onset (LS). ES can significantly affect the clinical outcome and occurrence of LS. Methods: We analyzed data from a prospective cohort of acute ischemic stroke patients between June 2018 and May 2020 in a neurology unit at a tertiary hospital. We screened all acute stroke patients and included consecutive patients older than 18 years of age, presenting with acute, first-ever neuroimaging-confirmed ischemic stroke. We excluded patients with a previous stroke, transient ischemic attacks, hemorrhagic stroke, cerebral venous thrombosis, prior history of seizures, or any other epileptogenic comorbidity. ES were classified as spontaneous seizures occurring within 1 week of the stroke. The main outcome assessed was the occurrence of ES. The secondary outcome was to determine predictors of ES and create an ES prediction score. Results: We screened 432 patients; of them, 291 were enrolled. ES occurred in 37 patients (12.7%). Cortical location (OR: 4.2), large artery disease subtype (OR: 2.9), mRS at presentation (OR: 1.4), use of anticoagulants (OR: 2.6), and hypertension (OR: 0.3) were significantly associated with the occurrence of ES. Patients with ES had a statistically significant worse clinical outcome at 3 months follow-up (P = 0.0072). Conclusion: We could formulate an ES prediction tool using the following components: (a) cortical location, (b) large vessel stroke, (c) mRS at admission, (d) anticoagulant use, and (e) presence of hypertension. This tool might help in treating patients at high risk for ES with prophylactic ASD, thereby preventing seizures and their complications.

Keywords: Cortical, early seizure, ES, seizure, stroke

Introduction

Stroke is the most common cause of epilepsy in the adult population above 35 years of age and accounts for approximately 45% of the newly diagnosed epilepsy cases over 60 years of age. Improvements in stroke management have reduced the mortality following a stroke while increasing the number of survivors with significant morbidity, of which patients with post-stroke seizures (PSSs) are an integral and important fraction. Studies have reported that approximately 5–20% of stroke patients develop PSS. These can be classified into early-onset (ES) and late-onset (LS) types. The cut-off between the two is arbitrary, and generally, seizures occurring one week after stroke are called LS. This distinction is important since their underlying seizure-inducing mechanisms and future risk of transformation to epilepsy are different. ES occurs due to acute neuronal injury and concomitant glutamate-mediated excitotoxicity, disruption of the blood-brain barrier, and ion channel dysfunction. LS occurs due to gliotic scarring and associated changes in the properties of the neuronal membrane, neurodegeneration, persistent inflammation, and altered synaptic plasticity, with eventual hyperexcitability and hyper-synchronization of neuronal activities. Definitions of ES and LS have varied between studies leading to a reported incidence of 2.2–33% and 3–67%, respectively. Despite this, the incidence of PSS is relatively consistent with two peaks: the first day and 6–12 months post-stroke.
Definitions
ES were classified as spontaneous seizures occurring within 1 week of the stroke event. Seizures occurring after 7 days of stroke were considered as LS. The NIHSS was used to assess the stroke severity and classified into mild (≤3), moderate (4–10), and severe (>10); and mRS was used to assess stroke disability. Stroke subtyping was done according to the TOAST criteria.

Inclusion and exclusion criteria
We screened all acute stroke patients and included consecutive patients older than 18 years of age, presenting with acute, first-ever neuroimaging-confirmed ischemic stroke. We excluded patients with a previously confirmed clinical history of stroke, transient ischemic attacks, primary hemorrhagic stroke, cerebral venous thrombosis, prior history of seizures/epilepsy, or any other potential epileptogenic comorbidities like brain tumors, arteriovenous malformations, primary central nervous system vasculitis, or hydrocephalus.

Data collection
A neurologist assessed all patients in the cohort, and baseline characteristics were gathered through a structured questionnaire. Patients were requested to report the use of any prescription drugs. Diagnosis of stroke was confirmed by brain imaging (MRI Brain/CT head). All participants were followed up with a face-to-face interview or telephonically in the outpatient services for a minimum period of 1 year, at three monthly intervals, to document recovery from stroke (mRS) and inquire about the occurrence of a seizure. The characteristics of seizures (type, severity, timing, and antiepileptic drugs) were recorded. All patients who reported seizures had a face-to-face interview. EEG was done only to rule out non-convulsive status epilepticus in patients with altered sensorium. For participants who were unable to answer our questions directly, their primary caregivers were interviewed. For patients where the consulting neurologist suspected an alternative cause for seizures other than the index ischemic stroke, relevant investigations were ordered to rule out any other pathology/stroke recurrence.

Outcomes
The main outcome assessed was the occurrence of early seizures. The secondary outcome was to determine the predictors of early seizures after acute ischemic stroke and to create an early seizure prediction score.

Statistical analysis
Statistical analysis was done using STATA, Version 14.0. Continuous variables are depicted as median with interquartile range or mean with standard deviation. Categorical variables are expressed as numbers and percentages. Student t-tests and Chi-square test were used as appropriate. The variables considered as possible predictors of early seizures were NIHSS and mRS at admission, stroke lateralization, cortical involvement, supratentorial location, age, sex, stroke risk factors, TOAST classification, recanalization procedures (thrombolysis/thrombectomy), hyponatremia and the use of antiplatelet/anticoagulants. Variables that were significant in univariate analysis were included in a multivariate analysis to determine risk factors for early seizures.

Results
We screened 432 patients and included 291 consecutive patients with acute ischemic stroke who fulfilled the inclusion criteria during our study period [Figure 1]. Ninety-eight patients were recruited from the PROLEVIS trial, and they did not have early seizures. No patients were lost to follow-up. Thirty-seven of the 291 patients (12.7%) had early seizures (<1 week). Unknown onset to bilateral tonic-clonic seizures was the most common seizure type (94.6%) followed by right focal seizures (5.4%). None of the patients had status epilepticus. The seizure occurred at the onset of stroke in one patient (2.7%) and within 24 h in 34 (91.9%) patients. Two patients had ES on the second day of stroke. Twenty-eight of these patients were started on an antiseizure drug (ASD) after the ES, with Levetiracetam being the most commonly prescribed drug. The baseline characteristics of all patients with and without ES are mentioned in Table 1.

Patients with ES were younger, had a more severe stroke at presentation (NIHSS and mRS), had a supratentorial and cortical location of the infarct, involving the MCA territory, and underwent lesser recanalization procedures (thrombolysis or mechanical thrombectomy). Large artery disease and cardioembolic subtypes were more common in patients with ES. Risk factors for stroke were similarly distributed except hypertension, which was less common in patients with early seizures.

Cortical location, large artery disease subtype, stroke disability (mRS) at presentation, the use of anticoagulants, and hypertension were significantly associated with the occurrence of early seizures by multivariate analysis [Table 2]. Cortical location was the strongest predictor for ES with an OR of 4.2, followed by large artery stroke subtype (OR: 2.9) and anticoagulant use (OR: 2.6). Stroke disability (defined by mRS) had an OR of 1.4 for ES. Hypertension was associated with a lower risk of ES (OR: 0.3).

Age at presentation had an inverse correlation and stroke severity (gauged by NIHSS score) had a direct correlation with early seizure occurrence and trended towards statistical significance.

Patients with ES had a statistically significant worse clinical outcome at 3 months follow-up compared to those without (mRS 3 vs 2; \( P = 0.0072 \)).
Early seizures occurred in 37 (12.7%) of acute ischemic stroke patients in our cohort. This is similar to the reported incidence of early seizures (2–20%) throughout the world. So et al.\textsuperscript{[5]} and Gupta et al.\textsuperscript{[19]} in their retrospective analysis found early seizures in 6% (33/535) and 33% (30/90) of their patient populations, respectively. The latter designated seizures occurring up to 2 weeks after stroke as early seizures. Prospective studies by Burn et al.\textsuperscript{[20]} and Labovitz et al.\textsuperscript{[21]} found early seizures in 1.8% (10/545) and 3.1% (22/704) of the studied populations, respectively. However, Burn et al.\textsuperscript{[20]} considered early seizures as those that occurred within the first 24 h. The recently published SeLECT score study\textsuperscript{[22]} found early seizures in 37 of their 1200 patients (3%). The majority of early seizures occurred within 24 h of the onset of stroke, which supports the hypothesis of local cellular or electrical dysfunction immediately after stroke, triggering a seizure.\textsuperscript{[23]}

Younger age of patients with early seizures may be possibly due to reduced cortical excitability with aging.\textsuperscript{[24,25]} A review by Feyissa et al.\textsuperscript{[23]} found a 10.7% prevalence of stroke-related epilepsy in individuals <65 years of age compared to 1.6% over the age of 85 years \((P < 0.001)\). The occurrence of early seizures significantly depended upon the location of the infarct, with cortical location predisposing to the same. This is in agreement with the study by Misirli et al.\textsuperscript{[25]} who found it to be the most important risk factor for the development of PSS, with an OR of 4.25. It was also associated with large artery disease stroke subtype. This might be because large artery disease tends to have larger infarct volumes and involves cortical brain tissue, increasing the probability for PSS.\textsuperscript{[6,16,26]} It also corroborated with the stroke severity based on the NIHSS and the functional disability measured by mRS. Thrombolysis was not found to be associated with the development of PSS. This could be because thrombolytics tend to decrease infarct volume, thereby protecting against PSS, which may hypothetically balance out the epileptogenicity due to their postulated neurotoxicity.\textsuperscript{[27,28]}

All stroke risk factors were found to be equally distributed between both the groups except hypertension, which was present in significantly lesser frequency in those with ES. This is in concordance with findings of decreased PSSs in patients with hypertension,\textsuperscript{[29,30]} although the exact pathophysiology is not clear. The ischemic penumbra is electrically irritable, and may be the focus for seizure activity.\textsuperscript{[29]} Elevated blood pressures might maintain its perfusion, thereby preventing seizure activity. A lesser prevalence of atherosclerotic risk factors in this subgroup of hypertensive individuals might also be responsible.\textsuperscript{[29]}

The use of anticoagulants was also found to be associated with an increased risk of ES. This could be because of increased hemorrhagic transformation tendencies associated with their use, which can act as an added irritant predisposing to seizures.\textsuperscript{[29]} Recent studies have revealed thrombin to be the major driving force not only for ES but also for LS by predisposing to maladaptive plasticity.\textsuperscript{[31]}

Early seizure patients were found to have a significantly worse functional outcome at 3 months. This is concordant with the findings of Arnst et al.\textsuperscript{[32]} who found a greater proportion of patients with mRS>2 in patients with PSSs than those without \((27.5% \text{ vs } 9.8%; P = 0.001)\).

Based on our findings, we would like to propose a model for predicting early seizures after an acute ischemic stroke.
The present models like PoSERS \(^{[33]}\) and SeLECT \(^{[22]}\) are only applicable to the prediction of late seizures. Strzelczyk \(et\ al\). \(et\ al\) formulated post-stroke epilepsy risk scale (PoSERS) after evaluating 264 consecutive stroke patients and identifying seven risk factors [Table 3] prospectively. \(^{[33]}\) It had high specificity and negative predictive value (99.6% and 98.8%, respectively) and moderate sensitivity and positive predictive value (70% and 87.5%, respectively). SeLECT score [Table 4] was developed and validated by Galovic \(M\ et\ al\). \(^{[22]}\) [Table 4] as a prediction tool for late seizures after an ischemic stroke. A six-point score indicates a late seizure risk of 18% in 1 year and 29% in 5 years after a stroke. A large artery stroke in the MCA territory with cortical involvement is likely to have a minimum score of 5, which translates to 11% (CI 8–13) at 1 year. In our cohort, even if we exclude the three points attributed to early seizure, still the total SELECT score is higher in patients with early seizure due to the cortical involvement and large artery stroke.

Our early seizure predictive model incorporates the five significant risk factors revealed in our prospective study (cortical location, large vessel stroke, mRS at admission, anticoagulant use, and presence of hypertension). Through this model, we

---

Table 1: Baseline characteristics in ischemic stroke patients with and without early seizures

| Characteristic                                    | Patients without ES (\(n=254\)) | Patients with ES (\(n=37\)) | \(P\)   |
|--------------------------------------------------|----------------------------------|-----------------------------|--------|
| Median age (in years)                             | 54±14                            | 49±15                        | 0.0243 |
| Median NIHSS at presentation                      | 6                                | 8                            | 0.0431 |
| Stroke severity (%)                               |                                  |                              |        |
| Mild (NIHSS ≤3)                                   | 16.1                             | 5.3                          | 0.32   |
| Moderate (NIHSS 4-10)                             | 55.1                             | 52.6                         |        |
| Severe (NIHSS >10)                                | 28.8                             | 42.1                         |        |
| Cortical location (%)                             | 38.9                             | 72.9                         | 0.000  |
| MCA territory involvement (%)                     | 79.5                             | 83.8                         | 0.545  |
| Supratentorial location                           | 83.1                             | 91.9                         | 0.169  |
| Stroke subtype (%)                                |                                  |                              | 0.028  |
| Large artery                                      | 32.3                             | 43.2                         |        |
| Cardioembolic                                     | 14.2                             | 18.9                         |        |
| Small vessel                                      | 29.1                             | 8.1                          |        |
| Other determined                                  | 5.1                              | 13.5                         |        |
| Undetermined                                      | 19.2                             | 16.2                         |        |
| Stroke risk factors (%)                           |                                  |                              |        |
| Diabetes mellitus                                 | 31.1                             | 21.6                         | 0.239  |
| Hypertension                                      | 66.9                             | 37.8                         | 0.001  |
| Dyslipidemia                                      | 2.4                              | 0                            | –      |
| Coronary artery disease                           | 11.0                             | 8.1                          | 0.591  |
| Atrial fibrillation                               | 5.1                              | 2.7                          | 0.521  |
| Smoking                                           | 36.2                             | 21.6                         | 0.081  |
| Alcohol intake                                    | 16.1                             | 13.5                         | 0.682  |
| Stroke laterality (%)                             |                                  |                              | 0.364  |
| Right                                             | 47.6                             | 40.5                         |        |
| Left                                              | 50.4                             | 54.0                         |        |
| Bilateral                                         | 2                                | 5.5                          |        |
| Sodium levels (%)                                 |                                  |                              | 0.676  |
| Hyponatremia (<135 mmol/L)                        | 14.8                             | 11.1                         |        |
| Thrombolysis (%)                                  |                                  |                              | 0.232  |
| Yes                                               | 8.3                              | 2.7                          |        |
| No                                                | 91.7                             | 97.3                         |        |
| Mechanical thrombectomy (%)                       |                                  |                              | 0.900  |
| Yes                                               | 2.4                              | 2.7                          |        |
| No                                                | 97.6                             | 97.3                         |        |
| Antiplatelet use                                  |                                  |                              | 0.076  |
| Yes                                               | 84.6                             | 73.0                         |        |
| No                                                | 15.4                             | 27.0                         |        |
| Anticoagulant use                                 |                                  |                              | 0.023  |
| Yes                                               | 11.0                             | 24.3                         |        |
| No                                                | 89.0                             | 75.7                         |        |
| Median mRS Presentation                           |                                  |                              | 0.0096 |
| 3-month follow-up                                 |                                  |                              | 0.0072 |
Table 2: Multivariate analysis

| Index                              | P     | Odds ratio | 95% Confidence Interval |
|------------------------------------|-------|------------|-------------------------|
| Cortical location                  | 0.000 | 4.22       | 1.96–9.11               |
| Hypertension                       | 0.001 | 0.30       | 0.14–0.61               |
| Anticoagulant use                  | 0.027 | 2.59       | 1.11–6.05               |
| Age                                | 0.050 | 0.97       | 0.95–1.00               |
| NIHSS at presentation              | 0.048 | 1.08       | 1.00–1.18               |
| mRS at presentation                | 0.004 | 1.38       | 1.10–1.73               |
| Large vessel disease               | 0.008 | 2.92       | 1.32–6.44               |

Table 3: Post-Stroke Epilepsy Risk Scale (PoSERS)[23]

| Item                                      | Risk |
|-------------------------------------------|------|
| Supratentorial stroke                     | 2    |
| ICH involving cortical areas              | 2    |
| Ischemia involving cortical or sub-cortical areas | 1    |
| Ischemia + ongoing neurological deficit   | 1    |
| Stroke caused neurological deficit with mRS>3 | 1    |
| Seizure occurred up to 14 days after stroke | 1    |
| Seizure occurred 15 days or later after stroke | 2    |

Table 4: SeLECT score[22]

| Variable                      | Score |
|-------------------------------|-------|
| Severity of stroke (Se)       |       |
| Mild (≤3)                     | 0     |
| Moderate (4-10)               | 1     |
| Severe (≥11)                  | 2     |
| Large artery atherosclerosis (L) |       |
| Yes                           | 1     |
| No                            | 0     |
| Early seizures (≤7 days) (E)  |       |
| Yes                           | 3     |
| No                            | 0     |
| Cortical involvement (C)      |       |
| Yes                           | 2     |
| No                            | 0     |
| Territory of MCA (T)          |       |
| Yes                           | 1     |
| No                            | 0     |

Table 2: Multivariate analysis

Our study has various strengths. The data were collected prospectively with regular in-person follow-up interviews and no losses to follow-up. Stroke was identified by neuro-imaging (with a majority of patients having undergone MRI of the brain as well, which makes delineation of cortical involvement more precise) and a neurologist verified the diagnosis of seizures. We only included the patients with the first imaging-identified stroke (previous strokes can predispose to seizures due to the presence of gliosis) and those who were antiseizure drug-naive. Symptomatic causes for seizures like hyponatremia were also analyzed for imparting additional early seizure risk. Twenty-eight (75.6%) of our patients with early seizures were prescribed an antiseizure drug, which is in keeping with the general practice of giving an antiepileptic after an early seizure (SeLECT study – ASD after ES – 52% in Swiss cohort, 67% in Austria cohort, 92% in German cohort, and 27% in Italian cohort). Moreover, the SeLECT study cohort included patients recruited until 2014, during which time, mechanical thrombectomy was only being done in Austria. Our cohort included seven patients who underwent a mechanical thrombectomy and data from novel stroke cohorts are needed to address the effect of these newer modalities of stroke treatment on post-stroke epilepsy.

As our study was conducted in a tertiary care center there is likely to be a referral bias. The sample size is also small. The patients recruited from the outpatient also had some missing data like NIHSS at the time of stroke onset, leading to an incomplete evaluation of some potential risk factors.

CONCLUSION AND IMPLICATIONS FOR THE FUTURE

Identification of predictors of early seizures poses three major clinical questions at two ends of a spectrum:

1. Should acute ischemic large artery stroke patients with cortical involvement be given prophylactic short-term antiseizure drug therapy for 24 h? Since the majority of early seizures occur within 24 h, should loading antiepileptic drug be a part of the initial drug treatment of stroke with cortical involvement?

2. Unlike late seizures, early seizures after stroke do not qualify for the definition of epilepsy. Hence, the decision to treat early seizures and duration of treatment is still a clinical equipoise, even though early seizures are an important risk factor for late seizures.

3. If an analogy can be drawn between acute symptomatic seizures following traumatic brain injury and development in some head-injured patients of post-traumatic epilepsy; then an acute stroke may also be considered and used as a model to study if ASDs or any other therapeutic manipulation can prevent the development of post-stroke epilepsy in these patients.

All three questions can be answered only by a high-quality multi-center randomized controlled trial.

Through our study we have formulated an early seizure prediction tool using the following components: (a) cortical location, (b) large vessel stroke, (c) mRS at admission, (d) anticoagulant use, and (e) the presence of hypertension. The prediction tool might help in segregating and treating patients at high risk for early seizures with prophylactic antiseizure drugs, thereby preventing seizures and their associated...
complications. Our model is presently being validated in another similar prospective cohort.

Financial support and sponsorship
This study is supported by a grant from Department of Science and Technology, Government of India (ECR/2017/000174) and the corresponding author had complete access to all the data and had the final responsibility to submit the article for publication. The study data can be accessed with a pertinent request to the same.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34:453-8.
2. Krueger H, Koot J, Hall RF, O’Callaghan C, Bayley M, Corbett D, et al. Prevalence of individuals experiencing the effects of stroke in Canada: Trends and projections. Stroke 2015;46:2226-31.
3. Bladin C, Alexandrov A, Bellavance A, Bornstein N, Chambers B, Coté R, et al. Seizures after stroke: A prospective multicentre study. Arch Neurol 2000;57:1617-22.
4. Davalos A, de Cendra E, Molins A, Ferrandiz M, Lopez-Pousa S, Genis D. Epileptic seizures at the onset of stroke. Cerebrovasc Dis 1992;2:327-31.
5. So EL, Annegers JF, Hauser WA, O’Brien PC, Whisnant JP. Population-based study of seizure disorders after cerebral infarction. Neurology 1996;46:350-5.
6. Beghi E, D’Alessandro R, Beretta S, Crespi V, Delaj L, et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology 2011;77:1785-93.
7. Laneman ME, Golinstok A, Norscini J, Granillo R. Risk factors for developing seizures after a stroke. Epilepsia 1993;34:141-3.
8. Reddy DS, Bhimani A, Kuruba R, Park MJ, Sohrabi F. Prospects of modelling poststroke epileptogenesis. J Neurosci Res 2017;95:1000-16.
9. Myint PK, Staufenberg EF, Sabanathan K. Post-stroke seizure and post-stroke epilepsy. Postgrad Med J 2006;82:568-72.
10. Lynch MW, Ratecki PA, Sutula TP. The effects of seizures on the brain. Curr Opin Neurol 1996;9:97-102.
11. Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004;35:1769-75.
12. Ferlazzo E, Gasparini S, Beghi E, Sueri C, Russo E, Leo A, et al. Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with metaanalysis of clinical risk factors. Epilepsia 2016;57:1205-14.
13. Stefanidou M, Das RR, Beiser AS, Sundar B, Kelly-Hays M, Kase CS, et al. Incidence of seizures following initial ischemic stroke in a community-based cohort: The Framingham Heart Study. Seizure 2017;47:105-10.
14. Arboix A, Comes E, García-Eroles L, Massons JB, Oliveres M, Balcells M. Prognostic value of very early seizures for in-hospital mortality in atherothrombotic infarction. Eur Neurol 2003;50:78-84.
15. Chung JM. Seizures in the acute stroke setting. Neurol Res 2014;36:403-6.
16. Zelano J. Poststroke epilepsy: Update and future directions. Ther Adv Neuro Disord 2016;9:424-35.
17. Zelano J, Redfors P, Åberg S, Kumlien E. Association between poststroke epilepsy and death: A nationwide cohort study. Eur Stroke J 2016;1:272-8.
18. Armzt RM, Rutten-Jacobs LC, Maaijwee NA, Schoonewaldt HC, Dorrestijn LD, van Dijk EJ, et al. Poststroke epilepsy is associated with a high mortality after a stroke at young age: Follow-up of transient ischemic attack and stroke patients and unelicited risk factor evaluation study. Stroke 2015;46:2309-11.
19. Gupta SR, Naheedy MH, Elias D, et al. Postinfarction seizures. A clinical study. Stroke 1988;19:477-81.
20. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C, et al. Epileptic seizures after a first stroke: The Oxfordshire Community Stroke Project. BMJ 1997;315:1582-7.
21. Labovitz DL, Hauser WA, Sacco RL. Prevalence and predictors of early seizure and status epilepticus after first stroke. Neurology 2001;57:200-206.
22. Galovic M, Kohler N, Erdelyi-Canavese B, Felbecker A, Siepel P, Conrad J, et al. Prediction of late seizures after ischemic stroke with a novel prognostic model (the SeLECT score): A multivariable prediction model development and validation study. Lancet Neurol 2018;17:143-52.
23. Feyissa AM, Hasan TF, Meschia JF. Stroke-related epilepsy. Eur J Neurosci 2019;26:18-26, e1-3.
24. Conrad J, Pawlowski M, Dogan M, Kovac S, Ritter MA, Evers S. Seizures after cerebrovascular events: Risk factors and clinical features. Seizure 2013;22:275-82.
25. Misirli H, Özge A, Somay G, Erdoğan N, Erkal H, Erenoğlu NY, et al. Seizure development after stroke. Int J Clin Pract 2006;60:1536-41.
26. Kulhari A, Sirbian D, Sundararajan S. Illustrative teaching case: Early onset seizures in stroke. Stroke 2014;45:e249-51.
27. Razvaini R, Haapanen M, Puitala J, Kaste M, Tatlisuamk T. Young adult ischaemic stroke related acute symptomatic and late seizures: Risk factors. Eur J Neurol 2013;20:1247-55.
28. Alvarez V, Rossetti AO, Papavasileiou V, Michel P. Acute seizures in acute ischemic stroke: Does thromboly-sis have a role to play? J Neurosurgery 2013;260:55-61.
29. Lahti AM, Saloheimo P, Huhtakangas J, Salminen H, Juvela S, Bode MK, et al. Post-stroke epilepsy in long-term survivors of primary intracerebral hemorrhage. Neurology 2017;88:2169-75.
30. Hundezzi Z, Shala A, Boshnjak D, Bytyqi S, Rrustemi J, Rama M, et al. Hypertension on admission is associated with a lower risk of early seizures after stroke. Seizure 2016;36:40-3.
31. Altman K, Shavit-Stein E, Maggio N. Post stroke seizures and epilepsy: From proteases to maladaptive plasticity. Front Cell Neurosci 2019. https://doi.org/10.3389/fncel.2019.00397.
32. Arntz RM, Maaijwee NAM, Rutten-Jacobs LCA, Schoonewaldt HC, Dorrestijn LD, van Dijk EJ, et al. Epilepsy after TIA or stroke in young patients impairs long-term functional outcome: The FUTURE Study. Neurology 2013;81:1907-13.
33. Strzelczyk A, Haag A, Raupach H, Herrendorf G, Hamer HM, Rosenow F, et al. Propective evaluation of a post-stroke epilepsy risk scale. J Neurol 2010;257:1322-6.
34. Zhang C, Wang X, Wang Y, Zhang JG, Hu W, Ge M, et al. Risk factors for post-stroke seizures: A systematic review and meta-analysis. Epilepsy Res 2014;108:1806-16.